New Report: Citius (CTXR) Trades 13 Million Shares on CoronaVirus and Candida Auris News.
Announces Mino-lok® Erdicates the Deadly and Untreatable C. Auris Bacteria.Announces License of Treatment for CoronaVirus Respiratory Failure.
Citius (CTXR) and Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19
Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19
Immunomedics (IMMU) up 100% Today or $2 Billion in Value & Stand Down VIII:
Bear Comments from Roubini, Jim Chanos, Jim Rogers and James A. Kostohryz
Don't Be That Guy in Denial!
Adding Organicell (BPSR) $0.02 to the Watch List.
Organicell (BBSR). New client, studying now. Thinly, thinly traded and expectedly volatile on an intra-day basis. Like what we’ve read so far...
Boo Ya. Brokerage Sets $12 Price Target for Athersys (ATHX) $2.96.
A major Wall Street firm that specializes in Bio and Medtech Companies has a $12 price target out on Athersys from one...
Adding Corbis Pharma (CRBP) $5.55 to Watch List.
Running Clinical Trials Full Steam With $46 Million Banked in Late February.
Not thinly, but lightly traded. Ready,...
Exosomes, Extracellular Vesicles, and the CoronaVirus.
Uploading a Series of Articles on Extracellular Vesicles, Including Potential Effects on the CoronaVirus and ARDS.
Article #1:...
FDA Authorizes Athersys (ATHX) to Initiate a Pivotal Clinical Trial!
FDA Authorizes Athersys to Initiate a Pivotal Clinical Trial Evaluating MultiStem® Cell Therapy in Patients With COVID-19 Induced Acute Respiratory Distress Syndrome.
Athersys (ATHX) Overview and Due Diligence links (Reddit)
I've (Dalek on Reddit) compiled a list of links that might be useful if you are disorganized like myself. If you are...
CDC’s Worst-Case Coronavirus Model: 214 Million Infected, 1.7 Million Dead (Intelligencer)
A recent CDC projection estimated that the U.S. coronavirus epidemic could infect between 160 million and 214 million people over a period...
Latest article
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
GeoVax (GOVX) Launches Vaccine Manufacturing System.
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
Manufacturing Process for Phase 3 and Commercial Production...
